{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:43:52Z","timestamp":1793339032351,"version":"4.5.0"},"reference-count":86,"publisher":"Baishideng Publishing Group Inc.","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3748\/wjg.v22.i28.6393","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T09:10:31Z","timestamp":1469524231000},"page":"6393","source":"Crossref","is-referenced-by-count":20,"title":["Hepatitis C virus: Promising discoveries and new treatments"],"prefix":"10.3748","volume":"22","author":[{"given":"Juliana Cristina Santiago","family":"Bastos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Aiello","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Cardia","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline Gonzalez","family":"Vigani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarice Weis","family":"Arns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2015.07.003"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i38.10790"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v8.i2.92"},{"key":"ref4","unstructured":"Madali\u0144ski K, Zakrzewska K, Ko\u0142akowska A, Godzik P. Epidemiology of HCV infection in Central and Eastern Europe. Przegl Epidemiol 2015;69:459-464, 581-584."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01934.x"},{"key":"ref6","unstructured":"World Health Organization. Hepatitis C, WHO fact sheet No. 164, updated July 2015. Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs164_apr2014\/en\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs164_apr2014\/en\/<\/ext-link>."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i4.1357"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2049936115585942"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.09.007"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.34181"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.33462"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80401-0"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.11.005"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201722200"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Xu Z, Choi J, Lu W, Ou JH. Hepatitis C virus f protein is a short-lived protein associated with the endoplasmic reticulum. J Virol 2003;77:1578-1583.","DOI":"10.1128\/JVI.77.2.1578-1583.2003"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.09.8"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i17.2416"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5&rsquo; noncoding region of hepatitis C virus. Proc Natl Acad Sci USA 1992;89:4942-4946.","DOI":"10.1073\/pnas.89.11.4942"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/v4102233"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.51.1.151"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20819"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/01.qco.0000104300.87920.03"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004;140:370-381.","DOI":"10.7326\/0003-4819-140-5-200403020-00033"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002881"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Kim T, Mudry RA, Rexrode CA, Pathak VK. Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J Virol 1996;70:7594-7602.","DOI":"10.1128\/JVI.70.11.7594-7602.1996"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)109"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002;76:4034-4043.","DOI":"10.1128\/JVI.76.8.4034-4043.2002"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01367.x"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.001"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.viruses.2004.11.002"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM. Quasispecies heterogeneity within the E1\/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005;79:3071-3083.","DOI":"10.1128\/JVI.79.5.3071-3083.2005"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i6.831"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 2006;299:261-284.","DOI":"10.1007\/3-540-26397-7_9"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Cody SH, Nainan OV, Garfein RS, Meyers H, Bell BP, Shapiro CN, Meeks EL, Pitt H, Mouzin E, Alter MJ. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch Intern Med 2002;162:345-350.","DOI":"10.1001\/archinte.162.3.345"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26635"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Hijikata M, Mizuno K, Rikihisa T, Shimizu YK, Iwamoto A, Nakajima N, Yoshikura H. Selective transmission of hepatitis C virus in vivo and in vitro. Arch Virol 1995;140:1623-1628.","DOI":"10.1007\/BF01322535"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1994.1582"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.023"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-011-9327-2"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00308-11"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26:71S-77S.","DOI":"10.1002\/hep.510260713"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-817.","DOI":"10.1016\/0016-5085(94)90131-7"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13514"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6841628"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12422"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1499.","DOI":"10.1056\/NEJM199811193392102"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808010"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26641"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein D, Rojter S, Schiff E, Davis M, Ruane PJ, Younes Z, Kalmeijer R. A phase 3, randomized, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir plus sofosbuvir in treatment- na&iuml;ve and treatment-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTMIST-1 [abstract]. Vienna: Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, April 22-26; 2015;Abstract LP14.","DOI":"10.1016\/S0168-8278(15)30168-9"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lawitz E, Matusow G, DeJesus E, Yoshida E, Felizarta F, Ghalib R, Godofsky E, Herring R, Poleynard G, Sheikh A. A phase 3, open-lable, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir and sofosbuvironn treatment-naive or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTMIST-2 [abstract]. Vienna: Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, April 22-26; 2015;Abstract LP04.","DOI":"10.1016\/S0168-8278(15)30158-6"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218DR"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27726"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.08.015"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-1086.","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12964"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04383-14"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1177\/0897190016632128"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12745"},{"key":"ref74","unstructured":"Crax&igrave; L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, Bruno R, Camm&agrave; C, Cicchetti A, Gasbarrini A. Prioritization of high-cost new drugs for HCV: making sustainability ethical. Eur Rev Med Pharmacol Sci 2016;20:1044-1051."},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12516"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-014-2302-1"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Finkielsztein LM, Moltrasio GY, Caputto ME, Castro EF, Cavallaro LV, Moglioni AG. What is known about the antiviral agents active against bovine viral diarrhea virus (BVDV)? Curr Med Chem 2010;17:2933-2955.","DOI":"10.2174\/092986710792065036"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/v5051219"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/745754"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.12.018"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.3390\/v4102197"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2011.11.109"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1590\/S1517-83822014005000030"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23587"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016464"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-153"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i28\/6393.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T09:23:28Z","timestamp":1600939408000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v22\/i28\/6393.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":86,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.v22.i28.6393","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}